参考文献
[1]
JiangF, JinT, Feng XL，et al.
Long-term outcomes and failure patterns of patients with nasopharyngeal carcinoma staged by magnetic resonance imaging in intensity-modulated radiotherapy era：the Zhejiang Cancer Hospital′s experience[J]．
J Cancer Res Ther，
2015，
11(
6)：
179-
184.
.
[2]
OuXM, ZhouX, ShiQ，et al.
Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy：new insight into the value of total dose of cisplatin and radiation boost[J]．
Oncotarget，
2015，
6(
35)：
38381-
38397.
.
[3]
LeeAWM, NgWT, ChanLLK，et al.
Evolution of treatment for nasopharyngeal cancer–success and setback in the intensity-modulated radiotherapy era[J]．
Radiother Oncol，
2014，
110(
3)：
377-
384.
.
[4]
LangJY, GaoL, GuoY，et al.
Comprehensive treatment of squamous cell cancer of head and neck：Chinese expert consensus 2013[J]．
Future Oncol，
2014，
10(
9)：
1635-
1648.
[5]
ChuaMLK, WeeJTS, HuiEP，et al.
Nasopharyngeal carcinoma[J]．
Lancet，
2016，
387(
10022)：
1012-
1024.
.
[6]
LeeAWM, NgWT, ChanLK，et al.
The strength/weakness of the AJCC/UICC staging system (7th edition) for nasopharyngeal cancer and suggestions for future improvement[J]．
Oral Oncol，
2012，
48(
10)：
1007-
1013.
.
[7]
LeeV, KwongD, LeungTW，et al.
Palliative systemic therapy for recurrent or metastatic nasopharyngeal carcinoma–How far have we achieved？[J]．
Crit Rev OncolHematol，
2017，
114：
13-
23.
.
[8]
AuE, AngPT.
A phase Ⅱ trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma[J]．
Ann Oncol，
1994，
5(
1)：
87-
89.
.
[9]
ChiKH, ChanWK, CooperDL，et al.
A phase Ⅱ study of outpatient chemotherapy with cisplatin，5-fluorouracil，and leucovorin in nasopharyngeal carcinoma[J]．
Cancer，
1994，
73(
2)：
247-
252.
.
[10]
PengPJ, OuXQ, LiaoH，et al.
Phase Ⅱ study of gemcitabine plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy[J]．
Ther Adv Med Oncol，
2016，
8(
3)：
153-
159.
.
[11]
ChuaDTT, ShamJST, AuGKH.
A phase Ⅱ study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma[J]．
Oral Oncol，
2005，
41(
6)：
589-
595.
.
[12]
LiW, BaiYT, WuM，et al.
Combined CT-guided radiofrequency ablation with systemic chemotherapy improves the survival for nasopharyngeal carcinoma with oligometastasis in liver：propensity score matching analysis[J]．
Oncotarget，
2017，
8(
32)：
52132-
52141.
.
[13]
田允铭，韩非，曾雷，等．
寡转移状态下初治鼻咽癌的预后及治疗模式探讨[J]．
中华放射肿瘤学杂志，
2016，
25(
11)：
1156-
1160.
.
TianYM, HanF, ZengL，et al. Prognosis and treatment of newly diagnosed nasopharyngeal carcinoma with oligometastases[J]．Chin J Radiat Oncol，2016，25(11)：1156-1160..
[14]
HuSX, HeXH, DongM，et al.
Systemic chemotherapy followed by locoregional definitive intensity-modulated radiation therapy yields prolonged survival in nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis[J]．
Med Oncol，
2015，
32(
9)：
224.
.
[15]
ZengL, TianYM, HuangY，et al.
Retrospective analysis of 234 nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis：therapeutic approaches and prognostic factors[J]．
PLoS One，
2014，
9(
9)：
e108070.
.
[16]
汪琛，李金高，邹嵩，等．
初治转移性鼻咽癌预后因素及治疗模式探讨[J]．
中山大学学报(医学科学版)，
2014，
35(
6)：
880-
888.
.
WangS, LiJG, ZouS，et al. The early cure metastatic prognostic factors and treatment of nasopharyngeal carcinoma (NPC) model discussed[J]．J Sun Yat-sen Univ (Med Sci)，2014，35(6)：880-888..
[17]
ChenMY, JiangR, GuoL，et al.
Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis[J]．
Chin J Cancer，
2013，
32(
11)：
604-
613.
.
[18]
TianYH, ZouWH, XiaoWW，et al.
Oligometastases in AJCC stage ⅠVc nasopharyngeal carcinoma：a subset with betteroverall survival[J]．
Head Neck，
2016，
38(
8)：
1152-
1157.
.
[19]
RusthovenCG, LanningRM, JonesBL，et al.
Metastatic nasopharyngeal carcinoma：patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy[J]．
RadiotherOncol，
2017，
124(
1)：
139-
146.
.
[20]
HuJY, KongL, GaoJ，et al.
Use of radiation therapy in metastatic nasopharyngeal cancer improves survival：a SEER analysis[J]．
Sci Rep，
2017，
7(
1)：
721.
.
[21]
ZouX, YouR, LiuH，et al.
Establishment and validation of M1 stage subdivisions forde novometastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment[J]．
Eur J Cancer，
2017，
77：
117-
126.
.
[22]
JiangR, YouR, PeiXQ，et al.
Development of a ten-signature classifier using a support vector machine integrated approach to subdivide the M1 stage into M1a and M1b stages of nasopharyngeal carcinoma with synchronous metastases to better predict patients′ survival[J]．
Oncotarget，
2016，
7(
3)：
3645-
3657.
.
[23]
蓝玉宏，田允铭，白力，等．
初治转移鼻咽癌疗后预后评分模型建立及分层治疗研究[J]．
中华放射肿瘤学杂志，
2015，
24(
4)：
421-
426.
.
LanYH, TianYM, BaiL，et al. Post-treatment prognostic score model establishment and stratified therapy for newly diagnosed metastatic nasopharyngeal carcinoma[J]．Chin J Radiat Oncol，2015，24(4)：421-426..
[24]
LiangY, BuJG, ChengJL，et al.
Selective radiotherapy after distant metastasis of nasopharyngeal carcinoma treated with dose-dense Cisplatin plus Fluorouracil[J]．
Asian Pac J Cancer Prev，
2015，
16(
14)：
6011-
6017.
.
[25]
GoldenEB, ChhabraA, ChachouaA，et al.
Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours：a proof-of-principle trial[J]．
Lancet Oncol，
2015，
16(
7)：
795-
803.
.
[26]
LinSJ, ThamIWK, PanJJ，et al.
Combined high-dose radiation therapy and systemic chemotherapy improves survivalin patients with newly diagnosed metastatic nasopharyngeal cancer[J]．
Am J Clin Oncol，
2012，
35(
5)：
474-
479.
.
[27]
WeichselbaumRR, HellmanS．
Oligometastases revisited[J]．
Nat Rev Clin Oncol，
2011，
8(
6)：
378-
382.
.
[28]
HellmanS, WeichselbaumRR.
Oligometastases[J]．
J Clin Oncol，
1995，
13(
1)：
8-
10.
.
[29]
FongYM, FortnerJ, SunRL，et al.
Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer：analysis of 1001 consecutive cases[J]．
Ann Surg，
1999，
230(
3)：
309-
321.
.
[30]
PastorinoU, BuyseM, FriedelG，et al.
Long-term results of lung metastasectomy：prognostic analyses based on 5206 cases[J]．
J Thorac Cardiovasc Surg，
1997，
113(
1)：
37-
49.
.
[31]
HuangJ, LiQJ, ZhengY，et al.
Partial hepatectomy for liver metastases from nasopharyngeal carcinoma：a comparative study and review of the literature[J]．
BMC Cancer，
2014，
14：
818.
.
[32]
ShenLJ, DongJ, LiS，et al.
M1 stage subdivision and treatment outcome of patients with bone-only metastasisof nasopharyngeal carcinoma[J]．
Oncologist，
2015，
20(
3)：
291-
298.
.
[33]
PanCC, WuPH, YuJR，et al.
Comparative survival analysis in patients with pulmonary metastases from nasopharyngeal carcinoma treated with radiofrequency ablation[J]．
Eur J Radiol，
2012，
81(
4)：
e473-
e477.
.
[34]
ZhangL, HuangY, HongSD，et al.
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma：a multicentre，randomised，open-label，phase 3 trial[J]．
Lancet，
2016，
388(
10054)：
1883-
1892.
.
[35]
ZhengW, ZongJF, HuangCB，et al.
Multimodality treatment may improve the survival rate of patients with metastatic nasopharyngeal carcinoma with good performance status[J]．
PLoS One，
2016，
11(
1)：
e0146771.
.
[36]
MaJ, WenZS, LinP，et al.
The results and prognosis of different treatment modalities for solitary metastatic lung tumor from nasopharyngeal carcinoma：a retrospective study of 105 cases[J]．
Chin J Cancer，
2010，
29(
9)：
787-
795.
.
[37]
JinY, CaiYC, CaoY，et al.
Radiofrequency ablation combined with systemic chemotherapy in nasopharyngeal carcinoma liver metastases improves response to treatment and survival outcomes[J]．
J Surg Oncol，
2012，
106(
3)：
322-
326.
.
[38]
LuTZ, GuoQJ, CuiXF，et al.
Prognostic evaluation of nasopharyngeal carcinoma with bone-only metastasis after therapy[J]．
Yonsei Med J，
2016，
57(
4)：
840-
845.
.
[39]
LeongSS, WeeJ, RajanS，et al.
Triplet combination of gemcitabine，paclitaxel，and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma[J]．
Cancer，
2008，
113(
6)：
1332-
1337.
.
[40]
HongRL, SheenTS, KoJY，et al.
Induction with mitomycin C，doxorubicin，cisplatin and maintenance with weekly 5-fluorouracil，leucovorin for treatment of metastatic nasopharyngeal carcinoma：a phase Ⅱ study[J]．
Br J Cancer，
1999，
80(
12)：
1962-
1967.
.
[41]
KoizumiW, NaraharaH, HaraT，et al.
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastriccancer (SPIRITS trial)：a phase Ⅲ trial[J]．
Lancet Oncol，
2008，
9(
3)：
215-
221.
.
[42]
YokotaT, OnozawaY, BokuN，et al.
S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy[J]．
Jpn J Clin Oncol，
2011，
41(
12)：
1351-
1357.
.
[43]
KimHS, KimHR, KimGM，et al.
The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma[J]．
Cancer Chemother Pharmacol，
2012，
70(
4)：
539-
546.
.
[44]
YouB, Le TourneauC, ChenEX，et al.
A phase Ⅱ trial of Erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma[J]．
Am J Clin Oncol，
2012，
35(
3)：
255-
260.
.
[45]
XueC, HuangY, HuangPY，et al.
Phase Ⅱ study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma[J]．
Ann Oncol，
2013，
24(
4)：
1055-
1061.
.
[46]
MaBBY, PoonTCW, ToKF，et al.
Prognostic significance of tumor angiogenesis，Ki 67，p53 oncoprotein，epidermalgrowth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma—a prospective study[J]．
Head Neck，
2003，
25(
10)：
864-
872.
.
[47]
VermorkenJB, MesiaR, RiveraF，et al.
Platinum-based chemotherapy plus cetuximab in head and neck cancer[J]．
N Engl J Med，
2008，
359(
11)：
1116-
1127.
.
[48]
XuTT, OuXM, ShenCY，et al.
Cetuximab in combination with chemoradiotherapy in the treatment of recurrent and/or metastatic nasopharyngeal carcinoma[J]．
Anti-Cancer Drugs，
2016，
27(
1)：
66-
70.
.
[49]
ElserC, SiuLL, WinquistE，et al.
Phase Ⅱ trial of Sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma[J]．
J Clin Oncol，
2007，
25(
24)：
3766-
3773.
.
[50]
JinT, LiB, ChenXZ.
A phase Ⅱ trial of Endostar combined with gemcitabine and cisplatin chemotherapy in patients with metastatic nasopharyngeal carcinoma (NCT01612286)[J]．
Oncol Res，
2013，
21(
6)：
317-
323.
.
[51]
PengPJ, ChengH, OuXQ，et al.
Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy：multi-institutional retrospective analysis[J]．
Drug Des，Devel Ther，
2014，
8：
1083-
1087.
.
[52]
ChuaDTT, ShamJST, AuGKH.
A phase Ⅱ study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy[J]．
Oral Oncol，
2003，
39(
4)：
361-
366.
.
[53]
PengPJ, LvBJ, WangZH，et al.
Multi-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens[J]．
Ther Adv Med Oncol，
2017，
9(
2)：
68-
74.
.
[54]
LeongSS, WeeJ, TayMH，et al.
Paclitaxel，carboplatin，and gemcitabine in metastatic nasopharyngeal carcinoma：a Phase Ⅱ trial using a triplet combination[J]．
Cancer，
2005，
103(
3)：
569-
575.
.
[55]
ChanATC, HsuMM, GohBC，et al.
Multicenter，phase Ⅱ study of Cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma[J]．
J Clin Oncol，
2005，
23(
15)：
3568-
3576.
.
[56]
HsuC, LeeSH, EjadiS，et al.
Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma：results of the KEYNOTE-028 study[J]．
J Clin Oncol，
2017.
.
[57]
ShenLJ, ChenC, LiBF，et al.
High weight loss during radiation treatment changes the prognosis in under-/normal weight nasopharyngeal carcinoma patients for the worse：a retrospective analysis of 2433 cases[J]．
PLoS One，
2013，
8(
7)：
e68660.
.
[58]
HuangPY, WangCT, CaoKJ，et al.
Pretreatment body mass index as an independent prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy：findings from a randomised trial[J]．
Eur J Cancer，
2013，
49(
8)：
1923-
1931.
.
